This appears to be partially driven by grade, as no survival difference was observed between GBM patients with Class I BRAF alterations and those with non-Class I alterations (p = 0.67, Fig. 4b), with median survival of 22 months across patients with GBM. The gene discussed is BRAF; the disease is glioblastoma.